Correlation of the prognostic value of FNDC4 in glioblastoma with macrophage polarization

Hongwu Li1,3†, Xiaofei Yan2† and Shaowu Ou1*

Abstract

Background: Glioblastoma is among the most malignant tumors in the central nervous system and characterized by strong invasion and poor prognosis. Fibronectin type III domain-containing 4 (FNDC4) plays various important roles in the human body, including participating in cellular metabolism and inflammatory responses to cardiovascular diseases, influencing immune cells, and exerting anti-inflammatory effects; however, the role of FNDC4 in glioblastoma has not been reported.

Methods: In this study, bioinformatics databases, including TCGA, CGGA, GTEx, and TIMER, were used to analyze the differential expression of FNDC4 genes and cell survival, in addition to investigating its relationship with immune cell infiltration. Additionally, we overexpressed FNDC4 in glioblastoma cell lines U87 and U251 by lentiviral transfection and detected changes in proliferation, cell cycle progression, and apoptosis. Following collection of monocytes from the peripheral blood of healthy individuals and transformation into M0 macrophages, we performed flow cytometry to detect the polarizing effect of exogenous FNDC4, as well as the effect of FNDC4-overexpressing glioblastoma cells on macrophage polarization in a co-culture system.

Results: We identified that significantly higher FNDC4 expression in glioblastoma tissue relative to normal brain tissue was associated with worse prognosis. Moreover, we found that FNDC4 overexpression in U87 and U251 cells resulted in increased proliferation and affected the S phase of tumor cells, whereas cell apoptosis remained unchanged. Furthermore, exogenous FNDC4 inhibited the M1 polarization of M0 macrophages without affecting M2 polarization; this was also observed in glioblastoma cells overexpressing FNDC4.

Conclusions: FNDC4 expression is elevated in glioblastoma, closely associated with poor prognosis, and promoted the proliferation of glioblastoma cells, affected the S phase of tumor cells while inhibiting macrophage polarization.

Keywords: Fibronectin type III domain containing 4, Glioblastoma, Prognosis, Macrophage

Background

In the central nervous system, glioblastoma is the most common malignant tumor and shows the highest degree of malignancy and mortality [1–3]. The main characteristic of glioblastoma is that it is extremely aggressive [4] and relapses very easily after surgical resection [5]. The prognosis of glioblastoma patients is poor, with a 5-year survival rate of < 10% [6]. Moreover, glioblastoma shows strong heterogeneity [7] accompanied by poor sensitivity to many radiotherapy and chemotherapy drugs [8]. These challenging pathological characteristics result in limited treatment options and highlight the importance of investigating the associated molecular mechanism to identify possible treatment strategies.

Fibronectin type III domain-containing (FNDC) is a highly conserved protein family [9], with five of the eight...
members found in humans playing important biological roles [10]. FNDC1 and FNDC4 levels are significantly elevated as inflammatory factors and play important roles in inflammatory bowel disease, making them attractive therapeutic targets [11]. In gastric cancer, FNDC1 expression is abnormally elevated and associated with poor prognosis [12], with similar findings reported for breast and pancreatic cancer [13, 14]. Additionally, studies show that FNDC3B plays an important regulatory role in glioblastoma, and that targeted regulation of FNDC3B can effectively inhibit glioblastoma proliferation and invasion [15, 16]. Furthermore, FNDC4 promotes tumor migration and invasion in hepatocellular carcinoma via the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway [17].

Despite the FNDC family showing important regulatory roles in tumors, the role of FNDC4 has not been evaluated in glioblastoma. In this study, we investigated the role(s) of FNDC4 in glioblastoma by combining bioinformatics analysis, functional experiments, and correlation analyses.

Methods

FNDC4 expression and survival analysis

FNDC4-expression data were obtained from several public databases, including The Cancer Genome Atlas (TCGA), China Cancer Genome Atlas (CGGA), and the Genotype–Tissue Expression project (GTEx), targeting information concerning grade IV primary glioblastoma.

Expression data in GTEx and TCGA were normalized and merged using the “limma” package in R (https://www.r-project.org/). We then used the “ggstatsplot” package to visualize the differential expression of FNDC4 in order to evaluate differences between normal brain tissue and glioblastoma tissue according to data from all three databases.

Survival information from patients (survival time and status) was obtained from TCGA and CGGA, respectively. The median FNDC4-expression value was segmented into high and low groups, and survival curves were generated using the “survminer” packages in R.

Correlation analysis of FNDC4 expression with the immune microenvironment

We used TCGA data on FNDC4 expression in glioblastoma to evaluate correlations with immune cell infiltration. The degree of immune invasion in each glioblastoma patient was calculated and scored using the “estimate” package in R. We then used the “ggplot2,” “ggpubr,” and “ggExtra” packages for correlation analyses, visualization of the results, and to generate immune-infiltration scores. Additionally, analyses were performed on FNDC4-expression and immune cell-infiltration data from the CIBERSORT database (https://cibersort.stanford.edu/) using the “e1071” and “preprocessCore” R packages.

Construction and culture of FNDC4-overexpressing cells

Glioblastoma cell lines U87 and U251 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The two cell lines were cultured in a liquid medium comprising 89% Dulbecco’s modified Eagle medium (DMEM; C11995500BT; Gibco, Gaithersburg, MD, USA), 10% fetal bovine serum (FBS; 10,099,141; Gibco), and 1% antibiotics in a 37°C incubator at 5% CO2. We used a lentiviral vector (Genechem Co. Ltd., Shanghai, China) to construct an FNDC4-overexpressing cell line. The transfection system comprised 2 mL DMEM, 2 μL polyamine (10 mg/mL), and 50 μL of the lentiviral vector (2 × 107 TU/mL) harboring a puromycin-resistance gene, with 10 μL of an empty lentiviral vector (1 × 108 TU/mL; pLKO.1 puro) used for the control [empty vector (EV) group]. After transfection, purinomycin was used to screen for 1 week, and purinomycin-resistant cells stably overexpressing FNDC4 were selected. DMEM containing 5 μg/mL purinomycin was used as the culture media in all subsequent experiments.

Western blotting and enzyme-linked immunosorbent assay (ELISA)

FNDC4-overexpressing U87 and U251 cells (FNDC4 OE U87/U251 and EV U87/U251) were collected and digested with radioimmunoprecipitation assay buffer containing protease- or phosphatase-inhibitor cocktails (PC102; Epizyme Biotech, Shanghai, China). Protein concentration was determined using a BCA working solution (ZJ101; Epizyme Biotech) using the ratio of electrophoresis solution to membrane-transfer solution adjusted according to the manufacturer’s instructions (500 ml: 500 ml). We performed sodium dodecyl sulfate polyacrylamide gel electrophoresis (KGP113K; Keygen Biotech Corp., Ltd., Jiangsu, China), followed by transfer of the protein bands to a polyvinylidene fluoride membrane (IPVH00010; Keygen Biotech Corp., Ltd.) and blocking with 5% skim milk. The membranes were incubated with anti-FNDC4 (1:1000; PA5-109,735; Thermo Fisher Scientific, Waltham, MA, USA) and anti-β-actin (1:2000; 66,009–1-Ig; Proteintech, Rosemont, IL, USA) overnight at 4°C, followed by incubation with secondary antibodies (1:10,000) and visualization by chemiluminescence.

We then performed ELISAs to detect exocrine levels of FNDC4 in the cell culture medium. Supernatant from the culture medium was obtained after serum-free starvation of each cell type was mixed with ELISA
reagents (MBS7208952; MyBioSource, San Diego, CA, USA). The ELISA microplate was filled with 50 μL of standard solution, a diluted sample (EV: 1:20; FNDC4 OE: 1:200), and 50 μL antibody cocktail. After treatment with 100 μL 3, 3′, 5, 5′-tetramethylbenzidine substrate solution, the experiment was terminated with 100 μL termination solution, followed by determination of absorbance at 450 nm using a microplate reader.

**Cell Counting Kit-8 (CCK-8) and migration assays**
EV U87, EV U251, FNDC4 OE U87, and FNDC4 OE U251 cells were seeded with 7.5 × 10^3 cells per well in 96-well plates for further culturing. Four parallel control groups were set in each group, and they were cultured for 24, 36, 48, 72, and 96 h, respectively. Next, 10 μl CCK-8 reagent was added to each well, and the solutions were allowed to react for 1.5 h; subsequently, the plate was placed in a full-wavelength microplate reader for absorbance measurements at 450 nm.

Transwell chambers (12-well format; Corning) were used to measure cell migration function. The above four kinds of cells were seeded into a chamber with a number of 2 × 10^5 cells and cultured in a serum-free medium of 200 μL. 800 μL of DMEM containing 10% FBS was added to the lower layer of the chamber and cultured in a constant temperature incubator at 37°C for 24 h. It was then fixed with methanol and stained with 0.04% trypan blue stain (Solarbio). Five fields were randomly selected under a 200 × microscope for shooting and counting.

**Cell cycle and apoptosis detection**
EV U87, EV U251, FNDC4 OE U87, and FNDC4 OE U251 cells were seeded with 2 × 10^5 cells per well in 96-well plates for further culturing. They were cultured for 48 h and digested by trypsin to allow cell precipitation.

We took 1 × 10^5 of these four cells and used them for cell cycle detection; 1 ml of pre-cooled 70% alcohol was added to fix the cells, and they were treated overnight at 4 °C. Propidium iodide staining solution containing RNA enzyme A was prepared according to the reagent instructions (Shanghai Beyotime Biotechnology; No. C1052); 0.5 ml of the staining solution was added to each well, and the plate was then placed in a 37 °C water bath, and incubated for 30 min away from light. After processing, it was transferred to a BD flow tube until machine testing.

Apoptosis was measured using 1 × 10^5 cells along with 500 μL binding buffer added to the four cell precipitates, 5 μL Annexin V–fluorescein isothiocyanate (FITC), and 5 μL PI (KGA107; Keygen Biotech Corp., Ltd.). The cells were mixed in a flow tube and incubated at room temperature for 10 min, followed by flow cytometry.

**Isolation and sorting of CD14⁺ peripheral blood mononuclear cells (PBMCs)**
This study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University (Shenyang, China), and healthy patients provided written informed consent prior to blood collection. Peripheral blood was collected from healthy volunteers and diluted with phosphate-buffered saline (PBS) at a 1:1 (v/v) ratio, followed by the addition of 20 mL Histopaque-1077 (10,771; Sigma-Aldrich, St. Louis, MO, USA) and human lymphocyte-separation solution and another round of dilution [PBS; 1:1 (v/v)]. The upper monolayer was obtained after centrifugation 2000 rpm for 25 min at 4 °C, and erythrocyte lysate was added to the cell suspension to obtain isolated peripheral monocytes after centrifugation. We then added a 2-mL cell suspension (1 × 10^8 cells/mL) to a flow tube along with 200 μL of reagent (17,858; STEMCELL Technologies, Vancouver, BC, Canada) for incubation at room temperature for 10 min. We then added 200 μL of magnetic beads to the sample for a 3-min incubation and arrangement over a magnetic pole (ThermoFisher), followed by attachment of the cells to the walls of the flow tube. CD14⁺ PBMCs were obtained by removing the flow tube from the magnetic pole and resuspending the cells with PBS.

**Effect of FNDC4 on macrophage polarization**
PBMCs were cultured in mixed medium comprising human monocytic colony stimulating factor (100 ng/mL) and 10% FBS–Roswell Park Memorial Institute-1640, and macrophages were obtained after ~72 h of culture. Polarized M1 and M2 macrophages were obtained using serum-free medium containing lipopolysaccharide (100 ng/mL; L4391; Sigma-Aldrich) and interleukin (IL)-4 (20 ng/mL; SRP3093; Sigma-Aldrich) and interleukin (IL)-10 (10 ng/mL; M6161; Sigma-Aldrich) and interleukin (IL)-12 (10 ng/mL; L3988; Sigma-Aldrich) and interleukin (IL)-18 (10 ng/mL; L3989; Sigma-Aldrich) after 24 h, respectively. The experiment was divided into three macrophage groups (M0, M0+LPS, and M0+IL-4), with human FNDC4 (AG-40B-0213; AdipoGen Life Sciences, San Diego, CA, USA) added to each group to detect its effect on macrophage polarization. After centrifugation, the precipitate was obtained, and 3 mL of flow staining buffer (554,657; BD Biosciences) containing mouse IgG was added for sealing treatment. CD68, CD80, and CD206 are markers of monocyte macrophages, M1 macrophages, and M2 macrophages, respectively. Groups were incubated with FITC-labeled mouse anti-human CD68 (562,117; BD Biosciences), APC-H7-labeled mouse anti-human CD80 (561,134;
Effect of co-culture of overexpressed FNDC4 and macrophages on polarization of macrophages

To evaluate the effect of co-culture on macrophage polarization, isolated monocytes were pretreated with LPS to obtain M1 macrophages, after which EV U87, EV U251, FNDC4 OE U87, and FNDC4 OE U251 cells were seeded into the lower chamber of a 6-well Transwell plate (2 × 10^5 cells/well), and M1-polarized macrophages were added to the upper layer. Cells were then incubated with the described antibodies (1:100) targeting cell-surface markers and evaluated using flow cytometry.

Validation of FNDC4 expression in glioblastoma cells

We used U87 and U251 cells to experimentally validate FNDC4 expression using western blot, revealing low FNDC4 levels in both cell lines. Therefore, we overexpressed FNDC4 in these cell lines via lentiviral vectors and confirmed successful transduction and exocrine secretion (Fig. 3a, b).

Evaluation of FNDC4 function in glioblastoma

Figure 4 shows that U87 and U251 proliferation was enhanced following FNDC4 overexpression after 48 h and 72 h, respectively; however, the migration abilities of both cell lines did not change significantly (Additional file 1). Additionally, flow cytometry results showed that FNDC4 overexpression did not affect glioblastoma cell apoptosis (Fig. 5 and Additional file 2), but affected the S phase of tumor cells (Fig. 6a, b; Additional file 3). Moreover, we found that PI3K/Akt signaling was also unaffected by FNDC4 overexpression in both cell lines (Additional file 4).

Exogenous FNDC4 inhibits the M1 polarization of macrophages

Following PBMC isolation and induction to M0 macrophages, we evaluated the effect of exogenous FNDC4, revealing almost no change in surface expression of CD80 or CD206 (Additional file 5a, b). Therefore, we used LPS (Additional file 5c) and IL-4 (Additional file 5e) to differentiate M0 macrophages into M1 and M2 subgroups, respectively, followed by exposure to exogenous FNDC4 (Additional file 5d, f). Figure 7a shows that LPS induction increased CD80 expression and decreased CD206 expression in M0 macrophages, resulting in a significantly higher CD80:CD206 ratio than that observed in control M0 macrophages and suggesting LPS-mediated polarization toward M1. Notably, subsequent exposure to exogenous FNDC4 significantly reduced the CD80:CD206 ratio (Fig. 7a), indicating that FNDC4 inhibited M1 polarization. However, Fig. 7b shows that IL-4 induction significantly decreased the CD80:CD206 ratio and promoted M2 polarization, whereas exposure to exogenous FNDC4 did not significantly alter the CD80:CD206 ratio, suggesting no significant effect by FNDC4 on M2 polarization.
FNDC4 overexpression in glioblastoma inhibits M1 macrophage polarization in the tumor immune microenvironment (TIM)

We performed Transwell experiments to evaluate the effect of FNDC4 overexpression in U87 and U251 cells on the M1 polarization of M0 macrophages. We found that the CD80:CD206 ratio decreased significantly when co-culturing FNDC4-overexpressing glioblastoma cells with M1 macrophages (Figs. 8e and 9e). These results suggest that FNDC4 overexpression in glioblastoma cells inhibits the M1 polarization of macrophages in the TIM.

Fig. 1 Bioinformatics analysis of FNDC4 in glioblastoma. a. Differential expression analysis of FNDC4 from TCGA database. b. Differential expression analysis of FNDC4 from CGGA database. c. Survival analysis of FNDC4 from TCGA database. d. Survival analysis of FNDC4 expression from CGGA database.
Discussion

FNDC protein family members play an important role in inflammation-related diseases and tumors. For example, FNDC3A can bind FAM46C to inhibit multiple myeloma progression by regulating autophagy [18], and FNDC5 regulates the conversion of white fat to brown fat [19, 20] and improves insulin resistance by regulating the macrophage polarization, thereby reducing the validation.

Fig. 2 Correlation analysis of FNDC4 expression in immune microenvironment in glioblastoma. a. Correlation of FNDC4 expression with immune microenvironment score in glioblastoma. b. Correlation analysis between FNDC4 expression and macrophages. c. Correlation analysis between FNDC4 expression and B cell. d. Correlation analysis between FNDC4 expression and CD4⁺ T cell. e. Correlation analysis between FNDC4 expression and CD8⁺ T cell.

Fig. 3 Verification of FNDC4 overexpression efficiency. a. FNDC4 overexpression verified by western blotting bands. b. Statistical analysis of exocrine FNDC4 overexpression was verified by ELISA. (Data are presented as mean ± SE)
response of adipose tissue [21]. Additionally, FNDC5 is a tumor regulator that affects tumor-proliferation and invasion abilities [22, 23]. Moreover, FNDC4 reportedly plays a role in promoting fat browning, similar to FNDC5 [24], and is an anti-inflammatory factor capable of improving colitis symptoms by specifically binding to macrophages [9, 25, 26]. Based on these findings, we speculated that FNDC4 may play an important regulatory role in tumor status and interactions with the TIM. This represents the first study to explore the potential mechanism and prognostic effect of FNDC4 in glioblastoma. The results showed that FNDC4 promoted tumor proliferation in glioblastoma, affected the S phase of tumor cells and inhibited the polarization of M0 macrophages to the M1 phenotype.

Increasing attention has focused on the role of immune cells in tumors, with the types and subtypes of infiltrating immune cells closely related to tumor occurrence and development [27, 28]. Macrophages are a primary component of the TIM and include in situ macrophages, such as microglia in the brain [26, 29, 30], and monocytes...
recruited through blood circulation (referred to as tumor-associated macrophages) [31, 32]. In the tumor microenvironment, pathogen-associated molecules, such as LPS, interferon-γ, granulocyte–macrophage colony stimulating factor, and tumor necrosis factor-α, can induce the polarization of M0 macrophages toward an M1 phenotype [33–35]. Upon M1 polarization, macrophages can secrete a variety of cytokines, such as IL-6 and IL-1β, which exert antitumor effects [36]. Additionally, M1 macrophages exhibit antigen-generating capacity and participate in the activation of a T helper cell 1-mediated immune response, thereby producing reactive oxygen species and proinflammatory cytokines to play a defensive role, eliminate tumor cells, and inhibiting tumor progression [37, 38].

In glioblastoma, there exist almost as many small glial cells (i.e., macrophages) as tumor cells [39, 40]. These macrophages secrete important transforming factors, cytokines, and chemokines to activate signaling molecules that induce the proliferation of tumor cells and increase the degree of tumor malignancy [41–43]. In the TIM of glioblastoma, M1-type microglia exert antitumor immune functions by producing proinflammatory cytokines [44, 45] and transcription signals as well as STAT1 [46–48]. However, in the present study, we found that FNDC4 promoted only the proliferation of glioblastoma cells, the potential mechanism associated with which may be related to the observed inhibition of M1 macrophage polarization by exocrine FNDC4. We speculated that in glioblastoma, exocrine FNDC4 plays a vital role in the TIM by suppressing M0 macrophage polarization to M1, thereby inhibiting their antitumor functions and leading to tumor cell proliferation, increased tumor malignancy, and subsequent poor prognosis. At the same time, we also speculated that overexpressed FNDC4 regulates tumor progression and affects tumor proliferation by affecting the S phase of tumor cells.

This study has limitations. Owing to the large number of immune cells present in the TIM, we selected only those identified as correlated with FNDC4 expression for evaluation; therefore, other immune cells need to be investigated. Additionally, the conclusions were obtained from in vitro experiments and, therefore, require validation using in vivo models.

**Conclusions**

This study explored the potential mechanism of FNDC4 in glioblastoma through bioinformatics analysis and cell-based experiments. We found that FNDC4 expression in tumor tissues was significantly higher than that in normal brain tissues, and that glioblastoma patients with elevated FNDC4 expression showed poor prognosis. Moreover, we showed that FNDC4 overexpression promoted tumor proliferation and affected the S phase of tumor cells in the absence of significant changes in cell apoptosis progression. Furthermore, the results indicated that exocrine FNDC4 was capable of inhibiting
macrophage polarization from an M0 to M1 phenotype, suggesting a potential role in the TIM.

Abbreviations
FNDC: Fibronectin type III domain-containing; GTEx: Genotype–tissue expression project; TCGA: The Cancer Genome Atlas; OS: Overall survival; CGGA: China Glioma Genome Atlas; CCK-8: Cell Counting Kit-8; EV: Empty vector; DMEM: Dulbecco’s modified Eagle medium; FBS: Fetal bovine serum; PBS: Phosphate-buffered saline; TIM: Tumor immune microenvironment; PBMCs: Peripheral blood mononuclear cells.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12935-022-02688-7.

Additional file 1. Migration assay. Images of (a, b) U87 cells and (d, e) U251 cells (EV and FNDC4-overexpression group) and (c) U87 and (f) U251 cell migration. Data represent the mean ± standard error.

Additional file 2. Apoptosis experiments. Flow cytometric diagram of apoptosis in (a, b) U87 cells and (c, d) U251 cells (EV and FNDC4-overexpression groups).

Additional file 3. Cell cycle experiments. Flow cytometric diagram of cell cycle progression in (a, b) U87 and (c, d) U251 cells (EV and FNDC4-overexpression groups).

Additional file 4. PI3K/Akt signaling validation.

Additional file 5. Effect of exogenous FNDC4 on macrophage polarization. (a–f) M0 macrophages were divided into groups (M0, M0+LPS, and M0+IL-4) that were treated with exogenous FNDC4 or left untreated. After 24 h, marker expression on the macrophage surface was detected using antibodies and flow cytometry.

Additional file 6. Summary of experimental data. CCK-8 and ELISA data.

Additional file 7. Western blot results. Uncropped results from Fig. 3a and Supplementary Material 4.

Acknowledgements
All authors would like to thank the Program of the Distinguished Professor of Liaoning Province (3110517003).

Author contributions
SO selected the research topic and conducted the guidance of the process of the topic. HL carried out experimental design and operation. XY processed the experimental data and wrote the paper.
Funding
The project is supported by the Program of the Distinguished Professor of Liaoning Province (3110517003).

Availability of data and materials
The data used in this study are all from public databases, including GTEx database (https://gtexportal.org/home/), TCGA database (https://www.cancer.gov/), CGGA database (http://www.cgga.org.cn/) and TIMER database (https://cistrome.shinyapps.io/timer/).

Declarations
Ethics approval and consent to participate
Our study was approved by the Ethics Committee of the First Affiliated Hospital of China Medical University. All participants offered written informed consent before surgery. The study conforms to the provisions of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors have declared that no competing interest exists.

Author details
1 Department of Neurosurgery, First Affiliated Hospital of China Medical University, Shenyang, China. 2 Department of Pathology, The First People’s Hospital of Nantong City (Affiliated Hospital 2 of Nantong University), Nantong, China. 3 Department of Neurosurgery, The First People’s Hospital of Nantong City (Affiliated Hospital 2 of Nantong University), Nantong, China.

Received: 21 April 2022 Accepted: 16 August 2022
Published online: 02 September 2022

References
1. Mars S, Xiao Y, Baschin M, Splittstoesser M, Altmann R, Moritz E, Jedlitschky G, Bien-Möller S, Schroeder H, Rauch B. The role of platelets in cancer pathophysiology: focus on malignant glioma. Cancers. 2019. https://doi.org/10.3390/cancers11040569.
2. Egaña L, Auzmendi-Iriarte J, Andermann M, Villanua J, Ruiz J, Elua-Prín A, Aldaz P, Querejeta A, Sarasqueta C, Zubía F, et al. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia hospital. Sci Rep. 2020;10(1):18445.
3. Rahman M, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, et al. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019;121(7):545–55.
4. Yin J, Zeng A, Zhang Z, Shi Z, Yan W, You Y. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. EBioMedicine. 2019:42:238–51.
5. Ollioso D, Caccese M, Santangelo A, Lippi G, Zagonel V, Cabrini G, Lombardi G, Dehecchi M. Serum exosomal microRNA-21, 222 and 124–3p as non-invasive predictive biomarkers in newly diagnosed high-grade gliomas: a prospective study. Cancers. 2021. https://doi.org/10.3390/cancers13123006.
6. Li R, Song Y, Fouladjan P, Arafat M, Chung R, Kohlhagen J, Gaig S. Three-dimensional printing of curcumin-loaded biodegradable and flexible scaffold for intracranial therapy of glioblastoma multiforme. Pharmacuetics. 2021. https://doi.org/10.3390/pharmaceutics13040471.
7. Porcù E, Maule F, Bosio D, Rampazzo E, Barbieri V, Zuccolotto G, Rosato A, Frasson C, Viola G, Gella Puppa A, et al. BMP4 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. Cell Death Differ. 2018;25(10):1808–22.
8. Niechi I, Uribe-Ojeda A, Erces J, Torres A, Uribe D, Rocha J, Silva P, Richter H, San Martín R, Quezada C. Adenosine depletion as a new strategy to decrease glioblastoma stem-like cells aggressiveness. Cells. 2019. https://doi.org/10.3390/cells8111353.
9. Bosma M, Gerling M, Pasto J, Georgiadi A, Graham E, Shilkova O, Iwata Y, Almer S, Söderman J, Toftgård R, et al. FNDC4 acts as an anti-inflammato-ry factor on macrophages and improves colitis in mice. Nat Commun. 2016;7.11314.
10. Kent W, Sugnet C, Furey T, Roskin K, Pringle T, Zehaler A, Haussler D. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.
11. Yunwens C, Shanhan G, Zhihui B, Saijun C, Hua Y. The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway. Mol Med Rep. 2021. https://doi.org/10.3892/ mmr.2021.12118.
12. Zhong M, Zhang Y, Yuan F, Peng Y, Wu J, Yuan J, Zhu W, Zhang Y. High FNDC1 expression correlates with poor prognosis in gastric cancer. Exp Ther Med. 2018;16(5):3847–54.
13. Yunwen C, Shanhan G, Zhihui B, Saijun C, Hua Y. The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway. Mol Med Rep. 2021. https://doi.org/10.3892/mmr.2021.12118.
14. Tan M, Schaffalitzky de Muckadell O, Jaergensen M. Gene expression net-work analysis of precursor lesions in familial pancreatic cancer. J Pancreat Cancer. 2020;6(1):73–84.
15. Xu H, Hu Y, Qiu W. Potential mechanisms of microRNA-129-5p in inhibiting cancer processes including viability, proliferation, migration and inva-siveness of glioblastoma cells U87 through targeting FNDC3B. Biomed Pharmacother. 2017;87:405–11.
16. Qi Z, Wang L, Xu Q. IncRNA LINCO0355 acts as a novel biomarker and promotes glioma biological activities via the regulation of miR-1225/ FNDC3B. Dis Markers. 2021;2021:1683129.
17. Wang B, Zheng R, Lu Y, Huang D, Liu J, Song J, Zheng S. FNDC4 acts as an extracellular factor to promote the invasiveness of hepatocellular carcinoma partly via the PI3K/Akt signaling pathway. Cancer Med. 2021;10(20):7242–52.
18. Manfrini N, Mancino M, Miluzio A, Oliveto S, Balestra M, Calamita P, Aliferay R, Rossi R, Sassoe-Pognetto M, Salio C, et al. FAM46C and FNDC3A are multiple myeloma tumor suppressors that act in concert to impairextein of protein aggregates and autophagy. Can Res. 2020;80(21):4693–706.
19. Bostrom P, Wu J, Jedydnichowski M, Korda G, Ye L, Lo J, Rasbach K, Bostrom E, Choi J, Long J, et al. A PCG1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8.
20. Elizondo-Montermayor L, González-Gil AM, Tamez-Rivera O, Toledo-Salinas C, Peschard-Franco M, Rodriguez-Gutierrez NA, Silva-Platas C, Garcia-Rivas G. Association between Irisin, hs-CRP, and metabolic status in children and adolescents with type 2 diabetes mellitus. Mediators Inflamm. 2019;2019:673718.
21. Xiong X, Geng Z, Zhu B, Zhang F, Han Y, Zhou Y, Wang J, Gao X, Chen Q, Li Y, et al. FNDC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity. Metab Clin Exp. 2018. https://doi.org/10.1016/j.metabol.2018.01.013.
22. Pinkowska A, Podhorska-Okłow M, Dziegieł J, Nowirska K. The role of Irisin in cancer disease. Cells. 2021. https://doi.org/10.3390/cells10041479.
23. Tsiáni E, Tsakindis N, Nouvelleti R, Jaglanian A, Kelltrown P. Current evidence of the role of the myokine irisin in Cancer. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13112628.
24. Frühbeck G, Fernández-Quiñanta B, Paniagua M, Hernández-Pardos A, Valentí V, Moncada R, Catalán V, Becerril S, Gómez-Ambrosi J, Portincasa P, et al. FNDC4, a novel adipokine that reduces lipogenesis and promotes fatty burning in human visceral adipocytes. Metabolism Clin Exp. 2020. https://doi.org/10.1016/j.metabol.2019.12118.
25. Almer S, Söderman J, Toftgård R, et al. FNDC4 acts as an anti-inflamma-toxic factor on macrophages and improves colitis in mice. Metabolism Clin Exp. 2020. https://doi.org/10.1016/j.metabol.2019.12118.
26. Zhang LX, Du J, Zhao YT, Wang J, Zhang S, Dubielecka PM, Wei L, Zhang S, Qin C, Chen Y, et al. Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium. J Appl Physiol. 2018;125(6):1968–78.
27. Tang Y, Zeng Z, Wang J, Li G, Huang C, Dong X, Feng Z. Combined signature of nine immune-related genes: a novel risk score for predicting prognosis in hepatocellular carcinoma. Am J Transl Res. 2020;12(4):1184–202.
28. Chen L, Yi X, Goswami S, Ahn Y, Roybal J, Yang Y, Diao L, Peng D, Peng D, Fradette J, et al. Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. Oncoimmunology. 2016;5(11):e1234570.
29. Anjum A, Yazid M, Faizi Daud M, Idris J, Ng A, Selvi Naicker A, Ismail O, Athi Kumar R, Lokanathan Y. Spinal cord injury: pathophysiology, molecular interactions, and underlying recovery mechanisms. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms2105279.
30. Howe MD, Furr JW, Munshi Y, Roy-O’Reilly MA, Maniskas ME, Koelhof-fer EC, d’Algie J, Singsing LH, McCullough LD, Urayama A. Transforming growth factor-beta promotes basement membrane fibrosis, alters perivascular cerebrospinal fluid distribution, and worsens neurological recovery in the aged brain after stroke. Geronescience. 2019;41(5):543–59.
31. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7.
32. Murray P, Allen J, Biswas S, Fisher E, Gilroy D, Goerdt S, Gordon S, Hamilton J, Ivashkiv L, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20.
33. Holden J, Attaad T, Laughton K, Mansell A, O’Brien-Simpson N, Reynolds E. Porphyromonas gingivalis lipopolysaccharide weakly activates M1 and M2 polarized mouse macrophages but induces inflammatory cytokines. Infect Immun. 2014;82(10):4190–203.
34. Rostam H, Reynolds P, Alexander M, Gadegaard N, Ghaemmaghami A. Image based Machine Learning for identification of macrophage subsets. Sci Rep. 2017;7(1):3521.
35. Macuszek M, Klak K, Rydz L, Verburg-van Kemenade B, Chadzinska M. Cortisol metabolism in carp macrophages: a role for macrophage-derived cortisol in M1/M2 polarization. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21238954.
36. Coscia M, Quaglinol E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinoma growth by targeting the mevalonate pathway. J Cell Mol Med. 2016;1(4):2893–15.
37. Porta C, Riboldi E, Ippolito A, Sica A. Molecular and epigenetic basis of macrophage polarized activation. Semin Immunol. 2015;27(4):237–48.
38. Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Savai R. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget. 2017;8(29):48436–52.
39. Yang S, Liu T, Cheng Y, Bai Y, Liang G. Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer. Cancer Sci. 2019;110(12):3639–49.
40. Nunez RE, Del Valle MM, Ortiz K, Almodovar L, Maniskas ME, Koelhof-fer EC, d’Algie J, Singsing LH, McCullough LD, Urayama A. Transforming growth factor-beta promotes basement membrane fibrosis, alters perivascular cerebrospinal fluid distribution, and worsens neurological recovery in the aged brain after stroke. Geronescience. 2019;41(5):543–59.
41. Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L, Xiao H, Wang B, Yi L, Wang Q, et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012;189(1):444–53.
42. Henrik Heiland D, Ravi V, Behringer S, Frenking J, Wurm J, Joseph K, Garrells N, Strähle J, Heynckes S, Grauvogel J, et al. Tumour-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun. 2019;10(1):2541.
43. Hull MA, Cuthbert RJ, Ko CWS, Scott DJ, Cartwright EJ, Hawcroft G, Perry SL, Ingram N, Carr IM, Markham AF, et al. Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc (Min+)/− mouse model of intestinal tumorigenesis. Sci Rep. 2017;7:10.1038/s41598-017-053.
44. Zhang J, Liu Y, Liu X, Li S, Cheng C, Chen S, Le W. Dynamic changes of CX3CL1/CX3CR1 axis during microglial activation and motor neuron loss in the spinal cord of ALS mouse model. Transl Neurodegener. 2018;7:35.
45. Sun Y, Zhou YQ, Liu YK, Zhang HQ, Hou GG, Meng GG, Hou Y. Potent anti-neuroinflammatory NF-κB small ka, Cytirilbb inhibitors based on 3,4-dihydroxyphenyl-1(2H)-one derivatives. J Enzyme Inhib Med Chem. 2020;35(1):1631–40.
46. Zhan X, Guo S, Li Y, Ran H, Huang H, Li L, Wu J, Wang X, Xiao D, Chen L, et al. Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation. J Exp Med. 2020. https://doi.org/10.1084/jem.20191340.
47. Wu S, Watabe K. The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. Front Biosci (Landmark edition). 2017;22(10):1805–29.
48. Wu A, Wei J, Kong L, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger A. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010;12(11):1113–25.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.